JP2025508024A5 - - Google Patents

Info

Publication number
JP2025508024A5
JP2025508024A5 JP2024553180A JP2024553180A JP2025508024A5 JP 2025508024 A5 JP2025508024 A5 JP 2025508024A5 JP 2024553180 A JP2024553180 A JP 2024553180A JP 2024553180 A JP2024553180 A JP 2024553180A JP 2025508024 A5 JP2025508024 A5 JP 2025508024A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
bispecific antibody
chain containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508024A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/052086 external-priority patent/WO2023170549A1/en
Publication of JP2025508024A publication Critical patent/JP2025508024A/ja
Publication of JP2025508024A5 publication Critical patent/JP2025508024A5/ja
Pending legal-status Critical Current

Links

JP2024553180A 2022-03-07 2023-03-06 Ctla-4及びpd-1二重特異性抗体を使用した治療方法 Pending JP2025508024A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263317200P 2022-03-07 2022-03-07
US63/317,200 2022-03-07
US202263347748P 2022-06-01 2022-06-01
US63/347,748 2022-06-01
US202263374815P 2022-09-07 2022-09-07
US63/374,815 2022-09-07
PCT/IB2023/052086 WO2023170549A1 (en) 2022-03-07 2023-03-06 Treatment methods using ctla-4 and pd-1 bispecific antibodies

Publications (2)

Publication Number Publication Date
JP2025508024A JP2025508024A (ja) 2025-03-21
JP2025508024A5 true JP2025508024A5 (cg-RX-API-DMAC7.html) 2026-07-06

Family

ID=87936206

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553180A Pending JP2025508024A (ja) 2022-03-07 2023-03-06 Ctla-4及びpd-1二重特異性抗体を使用した治療方法

Country Status (9)

Country Link
US (1) US20230322928A1 (cg-RX-API-DMAC7.html)
EP (1) EP4489781A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508024A (cg-RX-API-DMAC7.html)
KR (1) KR20240153603A (cg-RX-API-DMAC7.html)
AU (1) AU2023231766A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253514A1 (cg-RX-API-DMAC7.html)
IL (1) IL315307A (cg-RX-API-DMAC7.html)
TW (1) TW202400656A (cg-RX-API-DMAC7.html)
WO (1) WO2023170549A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3142751T (lt) * 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017515859A (ja) * 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
CN108367069B (zh) * 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
IL321475A (en) * 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
JP7599205B2 (ja) * 2018-06-01 2024-12-13 アンヘレス セラピューティクス インコーポレイテッド 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
EP4008730A4 (en) * 2019-08-02 2023-09-06 Akeso Pharmaceuticals, Inc. BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES
US20230074793A1 (en) * 2021-08-06 2023-03-09 Xencor, Inc. Treatment with a bispecific antibody that binds ctla4 and pd1
TW202348788A (zh) * 2022-04-01 2023-12-16 美商藝康美國公司 協同防汙劑組成物及使用其之方法

Similar Documents

Publication Publication Date Title
JP2023511595A5 (cg-RX-API-DMAC7.html)
TW201545759A (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
JP2022512851A (ja) がんの処置のための抗tigit抗体の投薬レジメン
US20210388090A1 (en) Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor
JP2024038034A (ja) 膀胱癌の抗pd-l1抗体治療
KR20180054492A (ko) CD66c에 특이적으로 결합하는 항체 및 그의 용도
JP2023545521A5 (cg-RX-API-DMAC7.html)
US20240218066A1 (en) Use of anti-pd-1 antibody in combination with first-line chemotherapy in treatment of advanced non-small cell lung cancer
TW202448943A (zh) 含有抗ceacam5抗體-藥物接合物、抗vegfr-2抗體及抗pd1/pd-l1抗體之抗腫瘤組合
JP2024536383A5 (cg-RX-API-DMAC7.html)
KR20240038769A (ko) 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법
EP4308243A1 (en) Methods for treating cancer with anti-ilt3 antibodies
US20190256603A1 (en) Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
KR20190107719A (ko) 세리티닙 및 항-pd-1 항체 분자의 조합물에 대한 투여 일정
TW202500194A (zh) 用於癌症治療中患者選擇之CEACAM5 mRNA分析
KR20240153603A (ko) Ctla-4 및 pd-1 이중특이적 항체를 사용한 치료 방법
JP2023512151A5 (cg-RX-API-DMAC7.html)
JP7817242B2 (ja) 鼻咽頭癌の治療における抗pd-1抗体の使用
WO2024213066A1 (en) Combination therapies involving grem1 antagonists for treatment of cancer
US20260130922A1 (en) Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
TW202515612A (zh) 使用薩西土珠單抗戈維特坎及抗pd—1抗體或其抗原結合片段治療非小細胞肺癌
JP2025520098A (ja) Nsclcを処置するためのバイオマーカーおよび方法
EA045953B1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
WO2025081048A1 (en) Methods of treating cancer using anti-cd22 antibody oligonucleotide conjugates